Clinical Trial Update: Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Envafolimab after ctDNA EGFR clearance by almonertinib in EGFR-mutant, PD-L1 positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)
• Envafolimab (envafolimab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN